More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores...
Leggi tuttoBrodalumab achieved high levels of lesion clearance in the majority of patients with moderate-to-severe psoriasis, with results sustained through 120 weeks...
Leggi tuttoPatients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy...
Leggi tuttoThe US Food and Drug Administration (FDA) has approved brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab is administered as an injection....
Leggi tuttoAn experimental, biologic treatment, brodalumab, appears to be more effective than ustekinumab in reducing psoriasis symptoms...
Leggi tutto